Column
- HOME
- Column
You can view the research column published every month by SMC Laboratories.
2025.02.02
SSc-ILD mouse model for simultaneous development of skin and lung fibrosis
We would like to introduce our SSc-ILD model – an improvement on our existing systemic scleroderma model – which is a more clinically relevant model of fibrosis that develops in both the skin and lungs. Systemic scleroderma is a progressive, rare disease that causes fibrosis not only in the skin but also in tissues…
2025.02.02
Acute Lung Injury mouse model shows similar symptoms to COVID-19 patients
We would like to introduce the Liposaccharide-induced Acute Lung Injury model (LPS model) – an ARDS model that shows symptoms similar to that of COVID-19 patients. It has been reported that COVID-19 patients develop symptoms of acute pneumonia and lung fibrosis. Acute pneumonia presents as an initial symptom of lung injury, and progresses to…
2025.02.02
Liver Orthotopic Xenograft mouse model
We would like to introduce the Liver Orthotopic Xenograft mouse model – a cancer model that also allows the evaluation of the tumor microenvironment. The number of deaths from cancer continues to rise as medical advances extend life spans. Therefore, there is a high requirement for the development of therapeutic drugs for various cancers,…
2025.02.02
Performance of FXR agonist pharmacology studies using our NASH model
We would like to share with you about our experience evaluating farnesoid X receptor (FXR) agonists in the world’s first mouse model that induces liver cancer from nonalcoholic steatohepatitis (NASH) – the STAM™ model – developed by SMC Laboratories, Inc. The nuclear receptor FXR is activated by bile acids and involved in the regulation…
2025.02.02
Introduction of our original chronic liver disease model mouse
We would like to introduce today the world’s first mouse model that induces liver cancer from nonalcoholic steatohepatitis (NASH) – the STAM™ model – developed by SMC Laboratories, Inc. The model, with a late-onset type 2 diabetic background, has the following advantages compared with other NASH models. This NASH model; reproduces the phenotype of…
2025.02.02
Growing demand for NASH therapeutics due to COVID-19 severity risk
It has been reported that various metabolic diseases are a factor in COVID-19 severity, and an increased risk for those with non-alcoholic liver disease (NASH/NAFLD) has also been reported. [Pawlotsky, J., Nat Rev Gastroenterol Hepatol,2020] Since there are currently no approved medications for NAFLD/NASH, new drug candidates are being developed. However, with the reported…
2025.02.02
COVID-19 and Pulmonary fibrosis
We would like to introduce an update regarding the relationship between pulmonary fibrosis and COVID-19, which is currently spreading worldwide. SARS-CoV-2 infection and subsequent continued inflammation have induced the features shown in below in COVID-19 patients. (Rothan et al., J Autoimmun., 2020; Weiren et al., Preprint, 2020 ). Similar features have been reported in…
2025.02.02
Galectin-3 in IPF model
We would like to introduce Galectin-3, a potential therapeutic target molecule in Idiopathic Pulmonary Fibrosis (IPF) model. Galectin-3 is a lectin protein which mediates the development of fibrosis, and has increased levels in macrophages in a variety of organs. It is reported that Galectin-3 null mice are resistant to liver, lung and heart fibrosis….
2025.02.02
Versatility of our proprietary STAM mice
We would like to introduce the versatility of our proprietary NASH-HCC model (“STAM™ mice”). We have provided a wide range of studies using STAM™ mice for many companies and universities. STAM™ mice offer the following characteristics. We can offer both preventive and therapeutic studies for multiple diseases such as steatosis, inflammation, fibrosis and…
2025.02.02
Results of drug efficacy evaluation studies using the NASH model_Microbiome
Today, we would like to introduce to you a study published by our client, MRM Health, in which they used our pre-clinical services to evaluate their test article in our proprietary NASH model called STAMTM. Title: A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo. …
We can help you advance your research.